27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Caregiver stress is associated with negative outcomes for both caregivers and care recipients. 5 key findings →
Design: randomized controlled trial Participants: 14 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Telemental health (TMH) for older patients has the potential to increase access to geriatric specialists, reduce travel times for patients and providers, and reduce ever growing healthcare costs. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Mini-Mental State Examination (MMSE) is recommended to test for cognitive impairment and to monitor medication response. 4 key findings →
Design: randomized controlled trial Participants: 7,073 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 346 of 374 (92.5%) intervention arm participants received some intervention (reach), and 305 of 374 (81.6%) attended ≥5 main sessions (predefined as adhering: dose). 5 key findings →
Design: randomized controlled trial Participants: 346 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The intervention revealed no substantial between-group differences in caregiver burden (β=-3.80, 95% CI -11.25 to 3.65, P=.32), quality of life (β=-1.55, 95% CI -6.59 to 3.49, P=.55), or social support (β=0.85, 95% CI -2.86 to 4.56, P=.65). 5 key findings →
Design: randomized controlled trial Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Attendance was good (82.8% attended ≥4/6 sessions). 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The majority of the assessed health care data did not show significant differences between urban and rural SHA inhabitants. 5 key findings →
Design: randomized controlled trial Participants: 133 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Vision difficulty and a larger friend network were negatively associated with adherence. 5 key findings →
Design: randomized controlled trial Participants: 191 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
56 individuals (mean (sd) age: 68.8 (4.2) years, 26 females, 24/32 intervention/control group) were included at baseline and 41 returned after an average of 28 months for the second assessment. 5 key findings →
Design: randomized controlled trial Participants: 56 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Clinical characteristics and demographics were similar between groups. 5 key findings →
Design: randomized controlled trial Participants: 89 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The inclusion criteria for peer-reviewed English publications from March 2020 to August 2022 consisted of studies related to telehealth services for people living with dementia and their family caregivers and studies conducted during the COVID-19 pandemic. 5 key findings →
Design: randomized controlled trial Participants: 24 Evidence: high
Full summary, score breakdown and related studies → Original source
Improving digital technology for caregivers requires studies with larger populations and longitudinal outcomes. 1 key finding →
Design: RCT Participants: 240 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
Between October 2021 and June 2022, 53 candidates were assessed; 29 met eligibility criteria and were randomised. 5 key findings →
Design: RCT Participants: 29 Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
One hundred sixteen participants consented and 93 (46 waitlist control, 47 intervention) were included in the analyses. 3 key findings →
Design: RCT Participants: 93 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
Controlling for pretest, the benefit-finding group had lower depression than the psychoeducation group at post-test, despite the fact that some caregivers found benefit-finding challenging. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Earlier NH admission of Australian compared to U.K. and U.S. subjects may be due to differences in health care, NH systems, availability, and affordability. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Donepezil and memantine have similar modest clinical and spectroscopic effect on mild to moderate AD. 3 key findings →
Design: randomized controlled trial Participants: 32 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
When compared to usual care, the practice guideline for optimal symptom relief did not relieve discomfort and symptoms in nursing home residents with dementia and pneumonia. 4 key findings →
Design: randomized controlled trial Participants: 16 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study demonstrates the acceptability and effectiveness of exercise on neurobehavioral function, even in older people more than 75 years of age. 1 key finding →
Design: randomized controlled trial Participants: 42 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In SURMOUNT-5, treatment with tirzepatide was associated with greater predicted 10-year CVD risk reduction compared with semaglutide. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Aging is associated with physiological changes that increase the risk of falls, impacting functional independence and quality of life. 4 key findings →
Design: randomized controlled trial Participants: 40 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Two hundred eighty dyads were enrolled. Caregivers during the intervention period reported lower levels of RSS of 0.7 points (standard deviation [SD]: 0.8) compared to the caregivers in the control period. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The ACT group reported significantly greater improvements in stress (P=.043) and psychological QoL (P=.014) in the posttest compared to the control group. 5 key findings →
Design: randomized controlled trial Participants: 16 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Eighty older adults with MCI (median age 86.50 years) participated, with an average attendance rate of 86.25% in the intervention group. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Data collection commenced in November 2023 and finished in July 2024, with the enrollment of 49 older adults with MCI (n=40, 81.6%, assigned to the experimental group [EG] and n=9, 18.4%, to the control group [CG]) conducted from October 2023 to April 2024. 5 key findings →
Design: randomized controlled trial Participants: 40 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →